000			01561nam a2200373 i 4500
001			2133312
003			StDuBDS
005			20240729133157.0
006			m|||||o||d||||||||
007			cr |||||||||||
008			230117s2017 enka fob 001|0|eng|d
020			_a9781910797389 (PDF ebook) : _cNo price
020			_z9781910797334 (pbk.) : _cNo price
020			_z9781910797389
040			_aStDuBDS _beng _cStDuBDS _erda _epn
060		4	_aWE 258
100	1		_aRamasamy, Karthik, _eauthor.
245	1	0	_aMultiple myeloma and plasma cell dyscrasias / _h[E-Book]
250			_aSecond edition.
264		1	_aAbingdon, Oxford : _bHealth Press, _c2017.
300			_a1 online resource (155 pages) : _billustrations (colour).
490	1		_aFast facts
500			_aThis edition also issued in print: 2017.
500			_aPrevious edition: 2015.
504			_aIncludes bibliographical references and index.
520	8		_aOur understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies.
521			_aSpecialized.
588			_aDescription based on online resource; title from PDF title page (viewed on January 17, 2023).
650		0	_aMultiple myeloma. _97046
650		2	_aMultiple Myeloma. _97046
700	1		_aLonial, Sagar, _eauthor.
830		0	_aFast facts.
856			_u#gotoholdings _yAccess resource
999			_c96882 _d96882